BioCentury
ARTICLE | Company News

Schering-Plough, Merck withdraw NDA, end JV

June 28, 2008 12:26 AM UTC

Schering-Plough (NYSE:SGP) and Merck (NYSE:MRK) withdrew an NDA for a fixed-dose combination tablet of loratadine and montelukast to treat allergic rhinitis. In April, the companies received a not approvable letter from FDA for the product. The companies said they would not further seek approval for the tablet (See BioCentury Extra, Monday, April 28, 2008). ...